Anti-SARS-CoV-2 potential of Cissampelos pareira L. identified by connectivity map-based analysis and in vitro studies
Vero cell
DOI:
10.1186/s12906-022-03584-3
Publication Date:
2022-04-22T16:02:54Z
AUTHORS (16)
ABSTRACT
Viral infections have a history of abrupt and severe eruptions through the years in form pandemics. And yet, definitive therapies or preventive measures are not present. Herbal medicines been source various antiviral compounds such as Oseltamivir, extracted using shikimic acid from star anise (Illicium verum) Acyclovir Carissa edulis FDA (Food Drug Administration) approved drugs. In this study, we dissect anti-coronavirus infection activity Cissampelos pareira L (Cipa) extract an integrative approach.We analysed signature similarities between predicted agents Cipa connectivity map ( https://clue.io/ ). Next, tested anti-SARS-COV-2 vitro. Molecular docking analyses constituents with key targets SARS-CoV2 protein viz. spike protein, RNA‑dependent RNA‑polymerase (RdRp) 3C‑like proteinase. was also performed. A three-way comparative analysis transcriptome, COVID-19 BALF transcriptome CMAP signatures small performed.Several antivirals showed high positive score apcidin, emetine, homoharringtonine etc. We observed 98% inhibition SARS-COV-2 replication infected Vero cell cultures whole extract. Some its prominent pure e.g. pareirarine, cissamine, magnoflorine exhibited 40-80% inhibition. Comparison genes enrichment biological processes like transcription regulation response to lipids, be downregulated while being upregulated COVID-19. that Triciribine, torin-1 VU-0365114-2 had 1 2, negative Cipa. Amongst all compounds, Magnoflorine Salutaridine most potent consistent strong silico binding profiles therapeutic targets.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (50)
CITATIONS (8)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....